Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus Biosciences' topically-applied erectile dysfunction treatment Vitaros has received Health Canada marketing approval.
Subscribe to our email newsletter
Apricus Bio said that Vitaros incorporates alprostadil, a well-recognised vasodilator that is currently marketed as an injectable product or an intra-urethral insert product for patients with erectile dysfunction.
Apricus Bio incorporated its proprietary NexACT drug delivery technology in the development of Vitaros as a patient-friendly topically-applied treatment for erectile dysfunction.
Apricus Bio president and CEO Bassam Damaj said that they were thrilled to have received the approval from Health Canada.
"Data from our clinical trials showed that patients responded to treatment within minutes of applying Vitaros," Damaj said.
"We view this Canadian approval as a validation of the NexACT technology as a transdermal delivery mechanism that is safe and effective.
"In addition, we will use this approval as the basis for seeking registration of the product for marketing in over 100 international markets."